TCM Biotech International Valuation

Q: What is the Fair Price of 4169 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

4169 (NT$55.8) is trading above our estimate of [[fair value]] (NT$1.27)

Is 4169 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4169 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4169 (NT$55.8) is trading above our estimate of fair value (NT$1.27)

Significantly Below Fair Value: 4169 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4169?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 4169. This is calculated by dividing 4169's market cap by their current preferred multiple.
What is 4169's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	NT$3.29b

4169 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3x
Enterprise Value/EBITDA	73.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 4169's PS Ratio compare to its peers?

The above table shows the PS ratio for 4169 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	34.1x
1783 Maxigen Biotech	6.1x	n/a	NT$3.8b
4132 Golden Biotechnology	63.7x	n/a	NT$4.0b
4194 Holy Stone Healthcare	11.6x	n/a	NT$2.7b
6564 Enimmune	55.1x	n/a	NT$2.4b
4169 TCM Biotech International	3.4x	n/a	NT$3.3b

Price-To-Sales vs Peers: 4169 is good value based on its Price-To-Sales Ratio (3.4x) compared to the peer average (34.1x).

Price to Earnings Ratio vs Industry

How does 4169's PE Ratio compare vs other companies in the TW Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	37.8%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	37.8%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: 4169 is good value based on its Price-To-Sales Ratio (3.4x) compared to the TW Biotechs industry average (24x).

Price to Sales Ratio vs Fair Ratio

What is 4169's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4169 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3.4x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 4169's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.